Blood test clues could personalize cancer therapy

NCT ID NCT05440838

Recruiting now Knowledge-focused Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

First seen Mar 20, 2026 · Last updated May 17, 2026 · Updated 10 times

Summary

This study is for adults with certain blood cancers (polycythemia vera, essential thrombocythemia, or pre-myelofibrosis) who are about to start their first treatment. The goal is to find biological markers, like genetic mutations and immune signals, that can predict whether a patient will respond well to standard therapies. By identifying non-responders early, doctors could switch to other treatments sooner, moving toward more personalized care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Chu Angers
RECRUITING

Angers, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Chu Brest
RECRUITING

Brest, 29606, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Chu Nantes
RECRUITING

Nantes, 44093, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Chu Poitiers
RECRUITING

Poitiers, 86021, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Chu Rennes
RECRUITING

Rennes, 35033, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Chu Tours
RECRUITING

Tours, 37044, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MYELOPROLIFERATIVE NEOPLASM